Gould Capital’s Takeda Pharmaceutical TAK Stock Holding History

Gould Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12K	Hold	70	–	–	﹤0.01%	201
2026 Q1	$1.3K	Hold	70	–	–	﹤0.01%	183
2025 Q4	$1.09K	Hold	70	–	–	﹤0.01%	189
2025 Q3	$1.02K	Hold	70	–	–	﹤0.01%	199
2025 Q2	$1.08K	Hold	70	–	–	﹤0.01%	194
2025 Q1	$1.04K	Hold	70	–	–	﹤0.01%	191
2024 Q4	$927	Hold	70	–	–	﹤0.01%	200
2024 Q3	$995	Hold	70	–	–	﹤0.01%	197
2024 Q2	$906	Hold	70	–	–	﹤0.01%	200
2024 Q1	$972	Hold	70	–	–	﹤0.01%	186
2023 Q4	$999	Hold	70	–	–	﹤0.01%	187
2023 Q3	$1.07K	Hold	70	–	–	﹤0.01%	184
2023 Q2	$1.1K	Hold	70	–	–	﹤0.01%	183
2023 Q1	$1.15K	Hold	70	–	–	﹤0.01%	188
2022 Q4	$1.09K	Hold	70	–	–	﹤0.01%	189
2022 Q3	$1K	Hold	70	–	–	﹤0.01%	194
2022 Q2	$1K	Hold	70	–	–	﹤0.01%	214
2022 Q1	$1K	Hold	70	–	–	﹤0.01%	193
2021 Q4	$1K	Buy	+70	New	+$982	﹤0.01%	201

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Gould Capital's TAK Position: Q2 2026 in Review

Gould Capital held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 70 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #201.

Gould Capital first reported a position in TAK in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.3K in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Gould Capital held 70 shares of Takeda Pharmaceutical worth $1.12K as of Q2 2026.
Gould Capital left its Takeda Pharmaceutical share count unchanged in Q2 2026.
Takeda Pharmaceutical made up ﹤0.01% of Gould Capital's portfolio in Q2 2026, its #201 holding.
Gould Capital first reported a position in Takeda Pharmaceutical in Q4 2021 and has held it in 19 quarters since.
Gould Capital's Takeda Pharmaceutical position peaked at $1.3K in Q1 2026.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Gould Capital's 13F filing for Q2 2026, filed 7 Aug 2026.